A Phase 3 interventional study of NVA237 and Placebo in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Novartis Pharmaceuticals. Completed at 32 sites in 4 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2014-08-08.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 22nd largest by enrollment, is one of 11 that started in 2012, is one of 33 in phase 3, and was the 22nd registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 11 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 460 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
117 studies in Pulmonary Disease, Chronic Obstructive by Novartis: none open now, none under way, none of them phase 3. Of 110 finished, 94 (85%) have results posted.
Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, this one is the 38th largest by enrollment of the 116 interventional ones that give a count, is one of 22 that started in 2012, is one of 59 in phase 3, and was the 67th registered.
Novartis’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2003.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 117 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess of the efficacy and safety of a once-daily, 50µg inhalation of NVA237 in moderate to severe chronic obstructive pulmonary disease (COPD) patients over 26 weeks treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NVA237 50 µg once daily delivered via a single dose dry powder inhaler
Drug: NVA237
Placebo once daily delivered via a single dose dry powder inhaler
Drug: Placebo
Delivered via a single dose dry powder inhaler
Delivered via a single dose dry powder inhaler
Trough Forced Expiratory Volume in One Second (FEV1)
Baseline FEV1 was defined as the average of the -45 min and -15 min FEV1 values taken on day 1 prior to the first dose of study medication. Trough FEV1 was defined as the mean of the post-dose 23 h 15 min and the 23 h 45 min FEV1 values. FEV1 was measured using central spirometry according to ATS/ERS standardization. Trough FEV1 was analyzed using a MIXED model for the full analysis set population. The model contained treatment as a fixed effect with the baseline FEV1 measurement, FEV1 prior to inhalation of short acting bronchodilator, FEV1 45 min post inhalation of short acting bronchodilator and baseline inhaled corticosteroids (ICS) use as covariates.
Time frame: 12 weeks
Transition Dyspnea Index (TDI) Score
Dyspnea was measured at baseline using the Baseline Dyspnea Index (BDI) and during the treatment period using the TDI, which captures changes from baseline. The BDI and TDI each have three domains: functional impairment, magnitude of task and magnitude of effort, and each domain scored from -3 (major deterioration) to +3 (major improvement), giving an overall score of -9 to +9. A negative score indicates deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.
Time frame: Baseline, week 12, week 26
Change From Baseline in Daily Rescue Medication Use (Number of Puffs)
The participant recorded the rescue medication taken in an electronic diary between visits and in the spirometry device during study visits. Daytime and nighttime rescue medication use (number of puffs) over 26 weeks was analyzed.
Time frame: Baseline, 26 weeks
24h Trough FEV1
Trough FEV1 was defined as the mean of the post-dose 23 h 15 min and the 23 h 45 min FEV1 values. This was measured using central spirometry according to ATS/ERS standardization. This was analyzed using the same MIXED model as specified for the primary analysis.
Time frame: Day 1, Week 26
FEV1 and Forced Vital Capacity (FVC)
FEV1 and FVC were measured using central spirometry according to ATS/ERS standardization. Both were analyzed using the same MIXED model as specified for the primary analysis.
Time frame: Day 1 at 5, 15, 30 minutes (min) and 1 hour (h) post dose; days 2, 86, 184 at 23 (h) 15 min and 23 h 45 min post dose; days 29, 85, 183 at -45 and -15 min pre-dose and 5, 15, and 30 min post dose
Peak FEV1
Peak FEV1 was defined as the maximum FEV1 0-4 h post-dose. Peak Fev1 was measured at 45min and 15min pre-dose and up to 4h post dose at day 1, week 12 and week 26, using central spirometry according to ATS/ERS standardization. It was analyzed using the same MIXED model as specified for the primary analysis.
Time frame: Day 1, week 12, week 26
Standardized FEV1 Area Under the Curve (AUC(5 Min-4 h)) Post-dose
The standardized (with respect to time) AUC for FEV1 was calculated between 5 min and 4h post morning dose at day 1, week 12 and week 26. The AUC (5 min-4 h) for FEV1 at each visit was analyzed using the same MIXED model as specified for the primary analysis.
Time frame: Day 1, week 12, week 26
Change From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Symptoms (Cough, Wheezing, Shortness of Breath, Sputum Volume, Sputum Color and Night Time Awakenings)
In an electronic diary, the participant responded to 6 questions twice daily to report on the degree of symptoms over the past 12 hours of the morning and evening. The questions covered the participant's degree of overall symptoms, and degrees of individual symptoms of coughing, wheezing, amount of sputum, color of sputum and breathlessness. Each question scored from 0 to 3 where 0 represented no symptom present and 3 represented the worst degree of that symptom. A negative change in symptom score indicates improvement.
Time frame: Baseline, 26 weeks
Time to First Moderate or Severe COPD Exacerbation
A COPD exacerbation was defined as a worsening of the following two or more major symptoms for at least 2 consecutive days:1) dyspnea; 2) sputum volume; 3) sputum purulence; or defined as a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: 1) sore throat; 2) colds (nasal discharge and/or nasal congestion); 3) fever without other cause; 4) cough; 5) wheeze. COPD exacerbations were recorded in the patient diary and other source documents.
Time frame: 26 weeks
Number of Moderate and Severe COPD Exacerbations
COPD exacerbations were recorded in the patient diary and other source documents. The rate of COPD exacerbations during the 26 week treatment period was analyzed using a generalized linear model assuming a negative binomial distribution.
Time frame: 26 weeks
The Total Score of the St George's Respiratory Questionnaire (SGRQ)
SGRQ is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity and impacts. The lowest possible score is zero and the highest possible score is 100. Higher scores correspond to greater impairment in quality of life. The health-related quality of life was measured using SGRQ. It was completed by the participant at the investigators site.
Time frame: Week 12, week 26
Participants were randomized in a 2: 1 ration to NVA237 and Placebo, respectively.
| Milestone | NVA237 | Placebo |
|---|---|---|
| Started | 306 | 154 |
| Safety set | 305 | 154 |
| Full analysis set (fas) | 305 | 154 |
| Fas, serial spirometry subgroup | 134 | 58 |
| Completed | 282 | 143 |
| Not completed | 24 | 11 |
| Withdrew: Patient's inability to use the device | 1 | 0 |
| Withdrew: Administrative problems | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 2 |
| Withdrew: Protocol deviation | 2 | 0 |
| Withdrew: Abnormal laboratory value | 2 | 0 |
| Withdrew: Death | 4 | 1 |
| Withdrew: Adverse event | 4 | 2 |
| Withdrew: Withdrawal by subject | 9 | 6 |
Baseline FEV1 was defined as the average of the -45 min and -15 min FEV1 values taken on day 1 prior to the first dose of study medication. Trough FEV1 was defined as the mean of the post-dose 23 h 15 min and the 23 h 45 min FEV1 values. FEV1 was measured using central spirometry according to ATS/ERS standardization. Trough FEV1 was analyzed using a MIXED model for the full analysis set population. The model contained treatment as a fixed effect with the baseline FEV1 measurement, FEV1 prior to inhalation of short acting bronchodilator, FEV1 45 min post inhalation of short acting bronchodilator and baseline inhaled corticosteroids (ICS) use as covariates.
| Liters | NVA237 | Placebo |
|---|---|---|
| Trough Forced Expiratory Volume in One Second (FEV1) | 1.204 ± 0.0135 | 1.063 ± 0.0160 |
Dyspnea was measured at baseline using the Baseline Dyspnea Index (BDI) and during the treatment period using the TDI, which captures changes from baseline. The BDI and TDI each have three domains: functional impairment, magnitude of task and magnitude of effort, and each domain scored from -3 (major deterioration) to +3 (major improvement), giving an overall score of -9 to +9. A negative score indicates deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.
| score | NVA237 | Placebo |
|---|---|---|
| week 12 (n=288,141) | 2.8 ± 0.32 | 1.6 ± 0.34 |
| week 26 (n=284,140) | 3.0 ± 0.31 | 2.0 ± 0.34 |
The participant recorded the rescue medication taken in an electronic diary between visits and in the spirometry device during study visits. Daytime and nighttime rescue medication use (number of puffs) over 26 weeks was analyzed.
| Number of puffs | NVA237 | Placebo |
|---|---|---|
| Change From Baseline in Daily Rescue Medication Use (Number of Puffs) | -0.77 ± 0.157 | -0.55 ± 0.186 |
Trough FEV1 was defined as the mean of the post-dose 23 h 15 min and the 23 h 45 min FEV1 values. This was measured using central spirometry according to ATS/ERS standardization. This was analyzed using the same MIXED model as specified for the primary analysis.
| Liters | NVA237 | Placebo |
|---|---|---|
| Day 1 (n=289,151) | 1.230 ± 0.0084 | 1.109 ± 0.0104 |
| Week 26 (n=281,143) | 1.195 ± 0.0140 | 1.059 ± 0.0171 |
FEV1 and FVC were measured using central spirometry according to ATS/ERS standardization. Both were analyzed using the same MIXED model as specified for the primary analysis.
| Liters | NVA237 | Placebo |
|---|---|---|
| FEV1, day 1, 5 min (n=281,143) | 1.199 ± 0.0060 | 1.112 ± 0.0072 |
| FEV1, day 1, 15 min (n=277,147) | 1.245 ± 0.0075 | 1.116 ± 0.0089 |
| FEV1, day 1, 30 min (n=283,145) | 1.265 ± 0.0076 | 1.111 ± 0.0090 |
| FEV1, day 1, 1 h (n=284,142) | 1.295 ± 0.0079 | 1.124 ± 0.0096 |
| FEV1, day 2, 23 h 15 min (n=267,137) | 1.228 ± 0.0086 | 1.101 ± 0.0108 |
| FEV1, day 2, 23 h 45 min min (n=272,140) | 1.230 ± 0.0092 | 1.107 ± 0.0112 |
| FEV1, day 29, -45 min (n=273,136) | 1.208 ± 0.0114 | 1.079 ± 0.0144 |
| FEV1, day 29, -15 min (n=280,142) | 1.226 ± 0.0113 | 1.097 ± 0.0142 |
| FEV1, day 29, 5 min (n=271,136) | 1.240 ± 0.0118 | 1.097 ± 0.0148 |
| FEV1, day 29, 15 min (n=272,135) | 1.259 ± 0.0117 | 1.103 ± 0.0147 |
| FEV1, day 29, 30 min (n=279,139) | 1.272 ± 0.0114 | 1.105 ± 0.0142 |
| FEV1, day 85, -45 min (n=269,130) | 1.179 ± 0.0118 | 1.050 ± 0.0147 |
| FEV1, day 85, -15 min (n=271,136) | 1.190 ± 0.0106 | 1.052 ± 0.0134 |
| FEV1, day 85, 5 min (n=262,130) | 1.229 ± 0.0119 | 1.059 ± 0.0147 |
| FEV1, day 85, 15 min (n=267,133) | 1.246 ± 0.0117 | 1.061 ± 0.0147 |
| FEV1, day 85, 30 min (n=273,137) | 1.263 ± 0.0129 | 1.077 ± 0.0156 |
| FEV1, day 85, 1 h (n=274,133) | 1.275 ± 0.0125 | 1.079 ± 0.0154 |
| FEV1, day 86, 23 h 15 min (n=261,127) | 1.195 ± 0.0146 | 1.057 ± 0.0175 |
| FEV1, day 86, 23 h 45 min (n=250,132) | 1.203 ± 0.0138 | 1.067 ± 0.0163 |
| FEV1, day 183, -45 min (n=262,135) | 1.176 ± 0.0148 | 1.032 ± 0.0176 |
| FEV1, day 183, - 15 min (n=265,135) | 1.179 ± 0.0130 | 1.052 ± 0.0165 |
| FEV1, day 183, 5 min (n=262,135) | 1.220 ± 0.0136 | 1.055 ± 0.0170 |
| FEV1, day 183, 15 min (n=261,140) | 1.233 ± 0.0139 | 1.070 ± 0.0169 |
| FEV1, day 183, 30 min (n=270,138) | 1.265 ± 0.0134 | 1.071 ± 0.0170 |
| FEV1, day 183, 1 h (n=263,135) | 1.263 ± 0.0137 | 1.075 ± 0.0168 |
| FEV1, day 184, 23 h 15 min (n=263,128) | 1.197 ± 0.0154 | 1.068 ± 0.0188 |
| FEV1, day 184, 23 h 45 min (n=266,132) | 1.196 ± 0.0144 | 1.058 ± 0.0180 |
| FVC, day 1, 5 min (n=281,143) | 2.925 ± 0.0184 | 2.739 ± 0.0220 |
| FVC, day 1, 15 min (n=277,147) | 2.992 ± 0.0252 | 2.759 ± 0.0288 |
| FVC, day 1, 30 min (n=283,145) | 3.041 ± 0.0235 | 2.761 ± 0.0280 |
| FVC, day 1, 1 h (n=284,142) | 3.044 ± 0.0240 | 2.755 ± 0.0286 |
| FVC, day 2, 23 h 15 min (n=267,137) | 2.953 ± 0.0275 | 2.716 ± 0.0326 |
| FVC, day 2, 23 h 45 min (n=272,140) | 2.981 ± 0.0261 | 2.744 ± 0.0311 |
| FVC, day 29, -45 min (n=273,136) | 2.908 ± 0.0324 | 2.690 ± 0.0375 |
| FVC, day 29, -15 min (n=280,142) | 2.927 ± 0.0312 | 2.730 ± 0.0371 |
| FVC, day 29, 5 min (n=271,136) | 2.970 ± 0.0292 | 2.725 ± 0.0353 |
| FVC, day 29, 15 min (n=272,135) | 2.993 ± 0.0276 | 2.751 ± 0.0339 |
| FVC, day 29, 30 min (n=279,139) | 2.995 ± 0.0287 | 2.737 ± 0.0341 |
| FVC, day 85, -45 min (n=269,130) | 2.854 ± 0.0321 | 2.611 ± 0.0385 |
| FVC, day 85, -15 min (n=271,136) | 2.898 ± 0.0318 | 2.627 ± 0.0373 |
| FVC, day 85, 5 min (n=262,130) | 2.927 ± 0.0321 | 2.633 ± 0.0380 |
| FVC, day 85, 15 min (n=267,133) | 2.954 ± 0.0328 | 2.647 ± 0.0387 |
| FVC, day 85, 30 min (n=273,137) | 2.977 ± 0.0330 | 2.695 ± 0.0383 |
| FVC, day 85, 1 h (n=274,133) | 2.987 ± 0.0347 | 2.662 ± 0.0400 |
| FVC, day 86, 23 h 15 min (n=261,127) | 2.908 ± 0.0366 | 2.612 ± 0.0429 |
| FVC, day 86, 23 h 45 min (n=250,132) | 2.894 ± 0.0360 | 2.671 ± 0.0412 |
| FVC, day 183, -45 min (n=262,135) | 2.858 ± 0.0379 | 2.604 ± 0.0430 |
| FVC, day 183, -15 min (n=265,135) | 2.862 ± 0.0359 | 2.633 ± 0.0415 |
| FVC, day 183, 5 min (n=262,135) | 2.927 ± 0.0368 | 2.672 ± 0.0426 |
| FVC, day 183, 15 min (n=261,140) | 2.957 ± 0.0365 | 2.679 ± 0.0420 |
| FVC, day 183, 30 min (n=270,138) | 2.988 ± 0.0366 | 2.707 ± 0.0428 |
| FVC, day 183, 1 h (n=263,135) | 2.941 ± 0.0401 | 2.668 ± 0.0453 |
| FVC, day 184, 23 h 15 min (n=263,128) | 2.869 ± 0.0386 | 2.664 ± 0.0452 |
| FVC, day 184, 23 h 45 min (n=266,132) | 2.894 ± 0.0402 | 2.647 ± 0.0472 |
Peak FEV1 was defined as the maximum FEV1 0-4 h post-dose. Peak Fev1 was measured at 45min and 15min pre-dose and up to 4h post dose at day 1, week 12 and week 26, using central spirometry according to ATS/ERS standardization. It was analyzed using the same MIXED model as specified for the primary analysis.
| Liters | NVA237 | Placebo |
|---|---|---|
| Day 1 (n=134,57) | 1.376 ± 0.0119 | 1.183 ± 0.0146 |
| Week 12 (n=125,56) | 1.347 ± 0.0207 | 1.140 ± 0.0245 |
| Week 26 (n=124,57) | 1.308 ± 0.0250 | 1.112 ± 0.0298 |
The standardized (with respect to time) AUC for FEV1 was calculated between 5 min and 4h post morning dose at day 1, week 12 and week 26. The AUC (5 min-4 h) for FEV1 at each visit was analyzed using the same MIXED model as specified for the primary analysis.
| Liters | NVA237 | Placebo |
|---|---|---|
| Day 1 (n=134,57) | 1.311 ± 0.0122 | 1.117 ± 0.0142 |
| Week 12 (n=125,56) | 1.286 ± 0.0204 | 1.080 ± 0.0241 |
| Week 26 (n=124,57) | 1.243 ± 0.0229 | 1.046 ± 0.0280 |
In an electronic diary, the participant responded to 6 questions twice daily to report on the degree of symptoms over the past 12 hours of the morning and evening. The questions covered the participant's degree of overall symptoms, and degrees of individual symptoms of coughing, wheezing, amount of sputum, color of sputum and breathlessness. Each question scored from 0 to 3 where 0 represented no symptom present and 3 represented the worst degree of that symptom. A negative change in symptom score indicates improvement.
| score | NVA237 | Placebo |
|---|---|---|
| Total symptom (n=296,150) | -1.16 ± 0.143 | -0.85 ± 0.164 |
| Respiratory symptom | -0.21 ± 0.033 | -0.12 ± 0.038 |
| Cough symptom | -0.24 ± 0.030 | -0.20 ± 0.036 |
| Wheeze symptom | -0.30 ± 0.030 | -0.22 ± 0.036 |
| Sputum production | -0.15 ± 0.034 | -0.11 ± 0.039 |
| Sputum color | -0.10 ± 0.025 | -0.10 ± 0.031 |
| Breathless symptom | -0.17 ± 0.030 | -0.10 ± 0.035 |
A COPD exacerbation was defined as a worsening of the following two or more major symptoms for at least 2 consecutive days:1) dyspnea; 2) sputum volume; 3) sputum purulence; or defined as a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: 1) sore throat; 2) colds (nasal discharge and/or nasal congestion); 3) fever without other cause; 4) cough; 5) wheeze. COPD exacerbations were recorded in the patient diary and other source documents.
| Days | NVA237 | Placebo |
|---|---|---|
| Time to First Moderate or Severe COPD Exacerbation | NA (NA to NA) | NA (NA to NA) |
COPD exacerbations were recorded in the patient diary and other source documents. The rate of COPD exacerbations during the 26 week treatment period was analyzed using a generalized linear model assuming a negative binomial distribution.
| Number of exacerbations | NVA237 | Placebo |
|---|---|---|
| Number of Moderate and Severe COPD Exacerbations | 0.2 ± 0.48 | 0.3 ± 0.58 |
SGRQ is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity and impacts. The lowest possible score is zero and the highest possible score is 100. Higher scores correspond to greater impairment in quality of life. The health-related quality of life was measured using SGRQ. It was completed by the participant at the investigators site.
| Score | NVA237 | Placebo |
|---|---|---|
| week 12 (n=293,147) | 32.35 ± 1.232 | 37.39 ± 1.399 |
| week 26 (n=288,144) | 31.02 ± 1.480 | 35.94 ± 1.641 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NVA237 | — | 17/305 (5.6%) | 81/305 (26.6%) |
| Placebo | — | 14/154 (9.1%) | 48/154 (31.2%) |
| Event | NVA237 | Placebo |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 10/305 | 9/154 |
| PneumoniaInfections and infestations | 3/305 | 3/154 |
| Lung infectionInfections and infestations | 2/305 | 0/154 |
| HypoproteinaemiaMetabolism and nutrition disorders | 2/305 | 0/154 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/305 | 1/154 |
| Pancreatitis acuteGastrointestinal disorders | 0/305 | 1/154 |
| Lower respiratory tract infectionInfections and infestations | 0/305 | 1/154 |
| Viral infectionInfections and infestations | 0/305 | 1/154 |
| Dupuytren's contractureMusculoskeletal and connective tissue disorders | 0/305 | 1/154 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/305 | 1/154 |
| Event | NVA237 | Placebo |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 49/305 | 32/154 |
| NasopharyngitisInfections and infestations | 36/305 | 15/154 |
| Upper respiratory tract infectionInfections and infestations | 18/305 | 12/154 |
| Age, Continuous(Years) | NVA237 | Placebo | Total |
|---|---|---|---|
| Mean | 64.6 ± 7.84 | 65.0 ± 8.29 | 64.7 ± 7.98 |
| Sex: Female, Male(Participants) | NVA237 | Placebo | Total |
|---|---|---|---|
| Female | 11 | 9 | 20 |
| Male | 294 | 145 | 439 |
The record gives a start of Mar 2012, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glycopyrrolate
Pulmonary Disease, Chronic Obstructive →